These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26504010)

  • 1. The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis.
    Göke A; Göke R; Ofner A; Herbst A; Lankat-Buttgereit B
    Anticancer Res; 2015 Nov; 35(11):5873-9. PubMed ID: 26504010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
    Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
    Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
    Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
    Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
    Takamura T; Horinaka M; Yasuda S; Toriyama S; Aono Y; Sowa Y; Miki T; Ukimura O; Sakai T
    Oncol Rep; 2018 Feb; 39(2):627-632. PubMed ID: 29207153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
    Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
    Xiao L; Du E; Homer-Bouthiette C; Hurley MM
    Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitory Eefects of the novel tyrosine kinase inhibitor BGJ398 against human leukemic cell line KG-1 cells].
    Jiang Y; Chao HY; Zhang XW; Zhou M; Lu XZ; Zhang R; He C; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):143-147. PubMed ID: 29562450
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.
    Göke F; Göke A; von Mässenhausen A; Franzen A; Sharma R; Kirsten R; Böhm D; Kristiansen G; Stenzinger A; Wynes M; Hirsch FR; Weichert W; Heasley L; Buettner R; Perner S
    Digestion; 2013; 88(3):172-81. PubMed ID: 24135816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic expression of herpes simplex virus-thymidine kinase gene in human non-small cell lung cancer cells conferred caspase-activated apoptosis sensitized by ganciclovir.
    Chiu CC; Kang YL; Yang TH; Huang CH; Fang K
    Int J Cancer; 2002 Dec; 102(4):328-33. PubMed ID: 12402300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
    Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
    Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
    Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
    Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
    Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
    Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
    Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
    Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
    Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.